Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia-Reference-Cited by-同舟云学术

Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia

Published:2014-10-07 Issue:2 Volume:23 Page:547-559
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Cortés de Miguel Sol,Calleja-Hernández Miguel Ángel,Menjón-Beltrán Salomón,Vallejo-Rodríguez Inmaculada

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-014-2459-x.pdf

Reference74 articles.

1. Fortner BV, Houts AC, Schwartzberg LS (2006) A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Support Oncol 4:472–478

2. Padilla G, Ropka ME (2005) Quality of life and chemotherapy-induced neutropenia. Cancer Nurs 28:167–171

3. Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23–35. doi: 10.3816/SCT.2003.n.002

4. Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984. doi: 10.1200/JCO.2004.00.7955

5. Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217. doi: 10.1136/bmj.38314.622095.8F

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of G-CSF in the prevention of cytostaticassociated adverse events during antitumor drug therapy;Meditsinskiy sovet = Medical Council;2024-07-25

2. An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer;The Breast;2023-12

3. A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe;Supportive Care in Cancer;2022-08-31

4. Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia;Future Oncology;2022-05

5. Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors;Life;2021-12-11